Nairametrics
  • Home
  • Exclusives
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
  • Markets
    • Cryptos
    • Commodities
    • Equities
      • Dividends
      • Stock Market
    • Fixed Income
    • Market Views
    • Securities
  • Industries
    • Company News
    • Consumer Goods
    • Content Partners
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Tech News
  • Economy
    • Get Data
    • Macro-Economic News
    • Research Analysis
  • Business News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Op-Eds
No Result
View All Result
  • Home
  • Exclusives
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
  • Markets
    • Cryptos
    • Commodities
    • Equities
      • Dividends
      • Stock Market
    • Fixed Income
    • Market Views
    • Securities
  • Industries
    • Company News
    • Consumer Goods
    • Content Partners
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Tech News
  • Economy
    • Get Data
    • Macro-Economic News
    • Research Analysis
  • Business News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Op-Eds
No Result
View All Result
Nairametrics
No Result
View All Result
Home Business News Coronavirus

Pfizer’s Covid pill, Paxlovid, receives FDA’s authorization as first oral antiviral pill

Chidinma Anyalewechi by Chidinma Anyalewechi
December 23, 2021
in Coronavirus
Pfizer’s Covid pill, Paxlovid, receives FDA’s authorization as first oral antiviral pill
Share on FacebookShare on TwitterShare on Linkedin

The U.S Food and Drug Administration has given emergency authorization to Pfizer’s Covid treatment pill and could be available to patients as early as the weekend.

The authorization of the covid pill, which is recommended for people at a high risk of developing severe Covid-19, has been described as a major milestone that could revolutionize the fight against the virus.

RelatedPosts

FG says Nigeria gathering vaccine producers to develop technology in case of future outbreaks

You can now go to United States without COVID-19 tests

The Centers for Disease Control and Prevention is expected to grant approval for distribution as soon as the drugmaker had already shipped some of the pills to the U.S to be prescribed following the FDA’s authorization.

The pill has been cleared only for patients who are aged 12 and above, possess mild to moderate Covid and are most likely to end up hospitalized or not survive. The agency said it should be prescribed as soon as possible after diagnosis and within five days of symptom onset.

The Director of the FDA’s Center for Drug Evaluation and Research, Dr. Patrizia Cavazonni, commenting on the authorization stated, “Today’s authorization introduces the first treatment for COVID-19 that is in the form of a pill that is taken orally — a major step forward in the fight against this global pandemic. This authorization provides a new tool to combat COVID-19 at a crucial time in the pandemic as new variants emerge and promises to make antiviral treatment more accessible to patients who are at high risk for progression to severe COVID-19.”

The company has said that it is ready to start delivery in the U.S. immediately after the U.S purchased 10 million courses of Pfizer’s treatment, Paxlovid, in a $5 billion deal.

The President of the United States, Joe Biden had disclosed in November that his administration is making effort towards ensuring that the treatment is free and accessible. He also stated that delivery of the treatment would commence by the New Year and all through 2022.

This development has been commended as the FDA’s authorization comes at a crucial time where hospitals across the U.S. have been repeatedly strained by a wave of Delta infections, and are now bracing for another wave of patients infected with the latest Omicron variant.

The Pfizer covid pill is the first oral antiviral drug authorized by the FDA. However, Merck, another drugmaker who also produced a covid treatment pill named, Molnupiravir, has contracted with the U.S. government to supply at least 3 million courses of its pill which is yet to be cleared by the agency, for $2.2 billion.

Related

Tags: Dr. Patrizia CavazonniPfizer’s Covid treatment pillU.S. Food and Drug Administration

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Hot forex
Cornerstone
Mega Millions
Polaris Bank
Access Bank
Bankers Committee
First bank


FCMB
Ikeja Electrics




    Business News | Stock Market | Money Market | Cryptos | Financial Literacy | SME |

    Recent News

    •  Investors in MTN Public Offer gain N35 billion in 6 months
    • Crypto Focused Hedge Funds are Shorting USDT – Reports
    • Customs seizes N1.3bn worth of smuggled goods in Ogun between May and June

    Follow us on social media:

    Recent News

    : MTN-Nigeria-CEO-Karl-Toriola

     Investors in MTN Public Offer gain N35 billion in 6 months

    June 28, 2022
    Tether, the most promising stable coin, now the third most valuable cryptocurrency

    Crypto Focused Hedge Funds are Shorting USDT – Reports

    June 27, 2022
    • ABOUT US
    • CONTACT US
    • PRODUCTS
    • ANDROID APP
    • iOS APP
    • DISCLAIMER
    • CAREERS
    • PRIVACY POLICY

    © 2022 Nairametrics

    No Result
    View All Result
    • Home
    • Exclusives
      • Financial Analysis
      • Corporate Stories
      • Interviews
      • Investigations
      • Metrics
    • Markets
      • Cryptos
      • Commodities
      • Equities
        • Dividends
        • Stock Market
      • Fixed Income
      • Market Views
      • Securities
    • Industries
      • Company News
      • Consumer Goods
      • Content Partners
      • Corporate deals
      • Corporate Press Releases
      • Energy
      • Entertainment
      • Financial Services
      • Hospitality & Travel
      • Manufacturing
      • Real Estate and Construction
      • Tech News
    • Economy
      • Get Data
      • Macro-Economic News
      • Research Analysis
    • Business News
    • Financial Literacy
      • Career tips
      • Personal Finance
    • Lifestyle
      • Billionaire Watch
      • Profiles
    • Opinions
      • Blurb
      • Op-Eds

    © 2022 Nairametrics

    Social Media Auto Publish Powered By : XYZScripts.com